E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Malignant hemopathy |
Hémopathie maligne |
|
E.1.1.1 | Medical condition in easily understood language |
Malignant hemopathy |
Hémopathie maligne |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Describe the evolution of thromboelastogram with tranexamic acid IV (usual dose of 3g / day versus a low dose of 1.5g / day versus no treatment) used to prevent bleeding observed during intensive chemotherapy in hematology during the period of severe thrombocytopenia (<50G / L). |
Décrire l’évolution du thromboélastogramme sous acide tranexamique IV (dose habituelle de 3g/j versus dose faible de 1.5g/j versus sans traitement) utilisé en prévention des saignements observés lors de chimiothérapies intensives en hématologie durant la période de thrombopénie sévère (<50G/L). |
|
E.2.2 | Secondary objectives of the trial |
- evaluation of the anti-fibrinolytic activity by the other parameters - overall assessment of coagulation - assessment of clot fibrin - incidence of bleeding episodes - tolerance (incidence of side effects: thromboembolic event, nausea, vomiting, diarrhea, color vision disorder, skin allergy, convulsions, acute tubular necrosis, death). |
- évaluation de l’activité anti-fibrinolytique par les autres paramètres - évaluation globale de la coagulation - évaluation de la fibrine du caillot - incidence d’épisodes hémorragiques - tolérance (incidence des effets secondaires : évènement thromboembolique, nausées, vomissements, diarrhée, trouble de la vision des couleurs, allergie cutanée, convulsions, nécrose tubulaire aiguë, décès). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Major patient affiliated or entitled to a social security scheme - Patient with haematological malignancy requiring intensive chemotherapy. - Hospitalization for aplasia with thrombocytopenia expected less than 10 G / L more than 5 days - Consent to participate in the signed study |
- Patient majeur affilié ou ayant droit d’un régime de sécurité sociale - Patient atteint d’hémopathie maligne nécessitant la réalisation d’une chimiothérapie intensive. - Hospitalisation pour aplasie avec thrombopénie attendue inférieure à 10 G/L plus de 5 jours - Consentement de participation à l’étude signé |
|
E.4 | Principal exclusion criteria |
- Pregnant woman, minor, protected major - Patient who is refractory to platelet transfusions or who requires a specific platelet delivery protocol - Patient on anticoagulant or platelet antiaggregant at baseline - Patient with a history of arterial or venous thromboembolism - Patient receiving a pro-coagulant agent (eg DDAVP, recombinant Factor VIIa, Prothrombin Complexes and / or antifibrinolytic agent within 48 hours prior to inclusion or known hypercoagulability state (induction of acute promyelocytic leukemia, disseminated intravascular coagulation, thrombotic purpura thrombocytopenic, history of veno-occlusive disease ...) - Patient with Grade 2 or greater bleeding from WHO within 7 days of inclusion - Patient with creatinine clearance <30 mL / min - Allergy known to tranexamic acid - History of convulsions - Patient already participating in a trial involving platelet transfusions, anti-fibrinolytics, other procoagulant agents or platelet growth factors - Patient having expressed his opposition to participate in the study |
- Femme enceinte, mineur, majeur protégé - Patient présentant un état réfractaire aux transfusions de plaquettes ou nécessitant un protocole spécifique de distribution de plaquettes - Patient sous anticoagulant ou antiagrégant plaquettaire à l’inclusion - Patient aux antécédents de maladie thromboembolique artérielle ou veineuse - Patient recevant un agent pro-coagulant (e.g. DDAVP, Facteur VIIa recombinant, Complexes Prothrombiniques et/ou un agent antifibrinolytique dans les 48 heures précédentes l’inclusion ou état d’hypercoagulabilité connu (induction leucémie aiguë promyélocytaire, coagulation intravasculaire disséminée, purpura thrombotique thrombocytopénique, antécédent de maladie veino-occlusive…) - Patient ayant présenté un saignement de grade 2 ou plus de l’OMS dans les 7 jours avant l’inclusion - Patient avec clairance de la créatininémie<30 mL/min - Allergie connue à l’acide tranexamique - Antécédents de convulsions - Patient participant déjà à un essai impliquant des transfusions plaquettaires, anti fibrinolytiques, autres agents procoagulants ou des facteurs de croissance plaquettaire - Patient ayant exprimé son opposition de participer à l’étude |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evolution of the thromboelastogram under the effect of tranexamic acid by the maximum amplitude of the curve EXTEM. |
Evolution du thromboélastogramme sous l’effet de l’acide tranexamique par l’amplitude maximale de la courbe EXTEM. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- evolution of the thromboelastogram under tranexamic acid by the other parameters of the EXTEM curve (time at the beginning of the clot, clot formation time, alpha angle, percentage of lysis after 30 min), - evolution of the clot fibrin by the FIBTEM curve (maximum amplitude, time at the beginning of the clot, clot formation time, alpha angle, percentage of lysis after 30 min), - incidence of WHO grade 2 or greater bleeding episodes during the first 30 days, number of serious grade 3-4 bleeding episodes, delay to 1st episode of bleeding, number of platelet concentrate transfusions, and erythrocytes, transfusion intervals, - incidence of side effects (thromboembolic event, nausea, vomiting, diarrhea, color vision disorder, skin allergy, seizures, acute tubular necrosis, death) |
- évolution du thromboélastogramme sous acide tranexamique par les autres paramètres de la courbe EXTEM (temps au début du caillot, temps de formation du caillot, angle alpha, pourcentage de lyse après 30min), - évolution de la fibrine du caillot par la courbe FIBTEM (amplitude maximale, temps au début du caillot, temps de formation du caillot, angle alpha, pourcentage de lyse après 30min), - incidence d’épisodes hémorragiques de grade 2 ou plus de l’OMS durant les 30 premiers jours, nombre d’épisodes hémorragiques graves de grade 3-4, délai jusqu’au 1er épisode de saignement, nombre de transfusions en concentrés de plaquettes et érythrocytaires, intervalles transfusionnels, - incidence des effets secondaires (évènement thromboembolique, nausées, vomissements, diarrhée, trouble de la vision des couleurs, allergie cutanée, convulsions, nécrose tubulaire aiguë, décès) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Pas de traitement ou le même traitement mais à une dose plus faible |
No treatment or same treatment with lower dose |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
Dernière visite du dernier patient inclus |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |